MDL 2724, In re Generic Pharmaceuticals Antitrust Pricing Litigation, encompasses potential class action lawsuits in which: (a) plaintiffs assert claims for price fixing of generic drugs in violation of the Sherman Act and/or state antitrust laws on behalf of overlapping putative nationwide classes of direct or indirect purchasers of generic pharmaceuticals; (b) the average market price of the subject generic pharmaceutical is alleged to have increased between 2012 and the present; (c) defendants are alleged to have effectuated the alleged conspiracy through direct company-to-company contacts and through joint activities undertaken through trade associations, in particular meetings of the Generic Pharmaceutical Association; and (d) the allegations stem from the same government investigation into anticompetitive conduct in the generic pharmaceuticals industry. Currently, there are claims concerning 18 drugs against a number of pharmaceutical manufacturers. The Judicial Panel on Multidistrict Litigation recently expanded the scope of the MDL to include claims brought by 40 States, proceeding through their Attorneys General.